LAG3 and rheumatoid arthritis: Additionally, previous studies demonstrated that abatacept treatment targeting T-cell responses might modulate Bregs and LAG3+ Tregs in RA patients [28,29], indicating therapy given to RA patients might affect the level of LAG3+ B cells.